Complete Genomics, a struggling DNA sequencing company in Silicon Valley, said on Monday that it had agreed to be acquired for USD 117.6 million by BGI-Shenzhen, a Chinese company that operates the world’s largest sequencing operation. The deal will need antitrust clearance, because of two key players in the DNA sequencing business in a highly capital intensive and research intensive industry, as well as clearance from a national security review by the Committee on Foreign Investment in the United States. It also requires approval from certain governmental authorities in China.
Featured News
Butterball Moves to End Turkey Antitrust Litigation With $34M Pact
Aug 23, 2026 by
CPI
Uber’s California Racketeering Case Against Lawyers, Doctors Moves Forward
Aug 23, 2026 by
CPI
Epic Challenges Apple’s Compliance With Brazil App Store Antitrust Settlement
Aug 23, 2026 by
CPI
EU Ends Pratt & Whitney Canada Antitrust Probe After Contract Changes
Aug 23, 2026 by
CPI
Paramount, California to Meet Monday on Antitrust Settlement
Aug 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Antipasto
Aug 24, 2026 by
CPI
“Anti-Monopoly” Antitrust Enforcement: Lessons Learned from the Biden Administration
Aug 24, 2026 by
Diana L. Moss
FTC v. Meta: The Importance of Quantitative Evidence in Antitrust
Aug 24, 2026 by
Dennis Carlton, John A. List, Allan Shampine, Hal Sider & Theresa Sullivan
Competitor Information Exchanges: Reducing Market Uncertainty Is What Matters, Not Level Of Detail
Aug 24, 2026 by
Kasia Czapracka, Assimakis Komninos, James Killick & Nina Frie
When Politics Meets Merger Control: 10 Transatlantic Takeaways
Aug 24, 2026 by
Rachel Brandenburger